Dr. François Nader M.D.
- n
- D
- i
Appointment to the Board
April 2022, previously Chair of BenevolentAI Ltd, appointed July 2021.
Experience and expertise
François served as Acting CEO of BenevolentAI between September 2023 and January 2024. Prior, François was chief executive officer of NPS Pharma. During his tenure, he transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. He won the Ernst and Young National Life Science Entrepreneur of the Year® award in 2013 and was awarded the Ellis Island Medal of Honor® in 2017.
Before NPS, François was a venture partner at Care Capital, LLC. Prior, he served on the North America leadership team of Aventis Pharma and its predecessor companies holding several executive positions including senior vice president, US integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
François is past chair of BioNJ, Acceleron Pharma and Prevail Therapeutics. He served as chair of Acceleron Pharma, Prevail Therapeutics, Neurvati Biosciences and BioNJ and on the board of BIO, Baxalta NPS Pharma, Alexion, Clementia Pharmaceuticals, Advanced Accelerator Applications and Noven.
François earned his French doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.
Current external appointments
François currently serves as board director of Moderna and independent director of Ring Therapeutics and as senior adviser to Blackstone Life Sciences.